Marc Thibonnier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4572024/publications.pdf

Version: 2024-02-01

331670 330143 1,964 37 21 37 h-index citations g-index papers 37 37 37 1402 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Effects of a shortâ€term cold exposure on circulating microRNAs and metabolic parameters in healthy adult subjects. Journal of Cellular and Molecular Medicine, 2022, 26, 548-562.	3.6	1
2	Metabolic Benefits of MicroRNA-22 Inhibition. Nucleic Acid Therapeutics, 2020, 30, 104-116.	3.6	17
3	Metabolic and energetic benefits of microRNA-22 inhibition. BMJ Open Diabetes Research and Care, 2020, 8, e001478.	2.8	22
4	Molecular Dynamics Study of the Hybridization between RNA and Modified Oligonucleotides. Journal of Chemical Theory and Computation, 2019, 15, 6422-6432.	5.3	17
5	Arrestin Binding to Calmodulin: A Direct Interaction Between Two Ubiquitous Signaling Proteins. Journal of Molecular Biology, 2006, 364, 955-963.	4.2	72
6	Soluble Mimics of the Cytoplasmic Face of the Human V1-Vascular Vasopressin Receptor Bind Arrestin2 and Calmodulin. Molecular Pharmacology, 2006, 70, 249-258.	2.3	7
7	Mapping the Binding Site of Six Nonpeptide Antagonists to the Human V ₂ -Renal Vasopressin Receptor. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 564-571.	2.5	54
8	A C-terminal segment of the V1R vasopressin receptor is unstructured in the crystal structure of its chimera with the maltose-binding protein. Acta Crystallographica Section F: Structural Biology Communications, 2005, 61, 341-345.	0.7	9
9	VARDENAFIL IMPROVED PATIENT SATISFACTION WITH ERECTILE HARDNESS, ORGASMIC FUNCTION AND SEXUAL EXPERIENCE IN MEN WITH ERECTILE DYSFUNCTION FOLLOWING NERVE SPARING RADICAL PROSTATECTOMY. Journal of Urology, 2005, 173, 2067-2071.	0.4	82
10	Vardenafil Improves Patient Satisfaction with Erection Hardness, Orgasmic Function, and Overall Sexual Experience, While Improving Quality of Life in Men with Erectile Dysfunction. Journal of Sexual Medicine, 2004, 1, 185-192.	0.6	40
11	Genetics of vasopressin receptors. Current Hypertension Reports, 2004, 6, 21-26.	3.5	16
12	Erection Quality Scale: Initial scale development and validation. Urology, 2004, 64, 351-356.	1.0	32
13	Vardenafil provides reliable efficacy over time in men with erectile dysfunction. Urology, 2004, 64, 1187-1195.	1.0	31
14	Vasopressin receptor antagonists in heart failure. Current Opinion in Pharmacology, 2003, 3, 683-687.	3.5	42
15	Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology, 2003, 61, 8-14.	1.0	136
16	Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists. Expert Opinion on Investigational Drugs, 2001, 10, 825-834.	4.1	14
17	Role of the human V sub>1vasopressin receptor COOH terminus in internalization and mitogenic signal transduction. American Journal of Physiology - Endocrinology and Metabolism, 2001, 281, E81-E92.	3.5	15
18	Study of V1-vascular Vasopressin Receptor Gene Microsatellite Polymorphisms in Human Essential Hypertension. Journal of Molecular and Cellular Cardiology, 2000, 32, 557-564.	1.9	71

#	Article	IF	Citations
19	Human Vascular Endothelial Cells Express Oxytocin Receptors*. Endocrinology, 1999, 140, 1301-1309.	2.8	281
20	Signal transduction pathways of the human V1-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors. Progress in Brain Research, 1999, 119, 147-161.	1.4	96
21	Molecular Pharmacology of Human Vasopressin Receptors. Advances in Experimental Medicine and Biology, 1998, 449, 251-276.	1.6	117
22	The Human V ₃ Pituitary Vasopressin Receptor: Ligand Binding Profile and Density-Dependent Signaling Pathways ¹ . Endocrinology, 1997, 138, 4109-4122.	2.8	115
23	Structure, Sequence, Expression, and Chromosomal Localization of the Human V1aVasopressin Receptor Gene. Genomics, 1996, 31, 327-334.	2.9	74
24	The genetics of hypertension. Current Opinion in Genetics and Development, 1995, 5, 362-370.	3.3	20
25	Cloning and characterization of the human V3 pituitary vasopressin receptor. FEBS Letters, 1994, 356, 215-220.	2.8	175
26	Cytoplasmic and nuclear signaling pathways of V1-vascular vasopressin receptors. Regulatory Peptides, $1993, 45, 79-84$.	1.9	36
27	Signal transduction of V1-vascular vasopressin receptors. Regulatory Peptides, 1992, 38, 1-11.	1.9	127
28	Multiple Signaling Pathways of V1-Vascular Vasopressin Receptors of A75rCells*. Endocrinology, 1991, 129, 2845-2856.	2.8	82
29	The Human Platelet Vasopressin Receptor and Its Intracellular Messengers. Journal of Cardiovascular Pharmacology, 1987, 10, 24-29.	1.9	26
30	Solubilization of human platelet vasopressin receptors. Life Sciences, 1987, 40, 439-445.	4.3	11
31	Binding characteristics of atrial natriuretic factor and the production of cyclic GMP in kidneys of DAHL salt-sensitive and salt-resistant rats. Biochemical and Biophysical Research Communications, 1987, 144, 1076-1083.	2.1	7
32	Acute Inhibition of the Renin-Angiotensin System. Journal of Cardiovascular Pharmacology, 1985, 7, S82-S85.	1.9	1
33	Improved Diagnosis of Unilateral Renal Artery Lesions After Captopril Administration. JAMA - Journal of the American Medical Association, 1984, 251, 56.	7.4	33
34	Osmoregulation and renal effects of vasopressin in normal and mildly hypertensive subjects. Kidney International, 1984, 25, 411-415.	5.2	13
35	Comparison of the hormonal and renal effects of captopril in severe essential and renovascular hypertension. American Journal of Cardiology, 1982, 49, 1447-1452.	1.6	45
36	Dynamic study of antidiuretic hormone during benign mineralocorticoid and metacorticoid hypertension. European Journal of Endocrinology, 1980, 95, 444-453.	3.7	5

#	Article	IF	CITATIONS
37	Abnormal regulation of antidiuretic hormone in idiopathic edema. American Journal of Medicine, 1979, 67, 67-73.	1.5	22